New Delhi: Russian Direct Investment Fund (RDIF) and Indian pharma company Hetero, have agreed to produce in India over 100 million doses per year of Sputnik V covid-19 vaccine in India, Russia's sovereign wealth fund said.
The production of the Russian Covid -19 vaccine is expected to start in the beginning of 2021.
“We are pleased to collaborate with RDIF as a manufacturing partner for the most anticipated Sputnik V vaccine for the treatment of Covid-19. While we look forward to the clinical trial results in India, we believe that manufacturing the product locally is crucial to enable swift access to patients," B. Murali Krishna Reddy, Director – International Marketing, Hetero Labs Limited commented.
RDIF on November 24 had announced positive results obtained during the second interim data analysis of the largest double-blind, randomized, placebo-controlled Phase III clinical trials in Russia involving 40,000 volunteers.